EP0835106A4 - Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten - Google Patents

Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten

Info

Publication number
EP0835106A4
EP0835106A4 EP96921794A EP96921794A EP0835106A4 EP 0835106 A4 EP0835106 A4 EP 0835106A4 EP 96921794 A EP96921794 A EP 96921794A EP 96921794 A EP96921794 A EP 96921794A EP 0835106 A4 EP0835106 A4 EP 0835106A4
Authority
EP
European Patent Office
Prior art keywords
ace inhibitor
kidney diseases
treating kidney
aii antagonist
aii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96921794A
Other languages
English (en)
French (fr)
Other versions
EP0835106A1 (de
Inventor
Giuseppe Remuzzi
Ronald S Eydelloth
Roger A Owen
Shahnaz Shahinfar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Merck Sharp and Dohme Chibret SAS
Merck and Co Inc
Original Assignee
Laboratories Merck Sharp and Dohme Chibret SAS
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602854.3A external-priority patent/GB9602854D0/en
Application filed by Laboratories Merck Sharp and Dohme Chibret SAS, Merck and Co Inc filed Critical Laboratories Merck Sharp and Dohme Chibret SAS
Publication of EP0835106A1 publication Critical patent/EP0835106A1/de
Publication of EP0835106A4 publication Critical patent/EP0835106A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP96921794A 1995-06-30 1996-06-26 Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten Withdrawn EP0835106A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77095P 1995-06-30 1995-06-30
US770P 1995-06-30
GBGB9602854.3A GB9602854D0 (en) 1996-02-13 1996-02-13 Method of treating renal disease using an ace inhibitor and an II antagonist
GB9602854 1996-02-13
PCT/US1996/010942 WO1997002032A1 (en) 1995-06-30 1996-06-26 Method of treating renal disease using an ace inhibitor and an aii antagonist

Publications (2)

Publication Number Publication Date
EP0835106A1 EP0835106A1 (de) 1998-04-15
EP0835106A4 true EP0835106A4 (de) 1998-09-30

Family

ID=26308665

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96921794A Withdrawn EP0835106A4 (de) 1995-06-30 1996-06-26 Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten

Country Status (5)

Country Link
EP (1) EP0835106A4 (de)
JP (1) JPH11508894A (de)
AU (1) AU716519B2 (de)
CA (1) CA2224451A1 (de)
WO (1) WO1997002032A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914158B2 (de) * 1996-04-05 2006-01-25 Takeda Chemical Industries, Ltd. Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
WO2001060362A1 (fr) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. INHIBITEURS DE TNF-$g(a)
CN1440283A (zh) * 2000-04-12 2003-09-03 诺瓦提斯公司 有机化合物的联合形式
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
HRP20030124A2 (en) * 2000-08-22 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
DK1420774T3 (da) * 2001-08-31 2008-11-24 Australian Biomedical Company Fremstilling og diabetisk anvendelse af gibberelliner
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
EP1452176A4 (de) * 2001-12-03 2009-01-21 Takeda Pharmaceutical Mittel zur verbesserung der insulinresistenz
DE10229180A1 (de) * 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
CN101439039B (zh) * 2003-05-09 2012-06-13 东丽株式会社 增强剂
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
ES2802251T3 (es) 2012-01-06 2021-01-18 Novartis Ag Compuestos heterocíclicos y métodos para su uso
CN116637115A (zh) * 2017-05-27 2023-08-25 广州喜鹊医药有限公司 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017771A1 (en) * 1990-05-11 1991-11-28 Pfizer Inc. Synergistic therapeutic compositions and methods
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
EP0527534A1 (de) * 1991-08-13 1993-02-17 Merck & Co. Inc. Chinolin- und Azachinolin-Derivate als Angiotensin-II-Antagonisten
EP0537937A2 (de) * 1991-10-07 1993-04-21 Merck & Co. Inc. Substituierte Pyrazino (2,3-D)Pyrimidinone als Angiotensin-II Antagoniste
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
WO1996031234A1 (en) * 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
WO1997037688A2 (en) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017771A1 (en) * 1990-05-11 1991-11-28 Pfizer Inc. Synergistic therapeutic compositions and methods
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
EP0527534A1 (de) * 1991-08-13 1993-02-17 Merck & Co. Inc. Chinolin- und Azachinolin-Derivate als Angiotensin-II-Antagonisten
EP0537937A2 (de) * 1991-10-07 1993-04-21 Merck & Co. Inc. Substituierte Pyrazino (2,3-D)Pyrimidinone als Angiotensin-II Antagoniste
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
WO1996031234A1 (en) * 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
WO1997037688A2 (en) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURDMANN ET AL: "Prevention of Experimental Cyclosporin-Induced Interstitial Fibrosis by Losartan and Enalapril", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 269, no. 4, October 1995 (1995-10-01), pages f491 - f499, XP002072709 *
POLLOCK ET AL: "Angiotensin II Receptor Blockade Improves Renal Function in Rats with Reduced Renal Mass", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 367, no. 2, 1993, pages 657 - 663, XP002072710 *
See also references of WO9702032A1 *

Also Published As

Publication number Publication date
AU6291696A (en) 1997-02-05
EP0835106A1 (de) 1998-04-15
CA2224451A1 (en) 1997-01-23
AU716519B2 (en) 2000-02-24
JPH11508894A (ja) 1999-08-03
WO1997002032A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
DE69501817D1 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
DE69603838D1 (de) Verfahren zur behandlung von gasen
DE69806970D1 (de) Verfahren zur behandlung von hartgeweben
DE69425372D1 (de) Verfahren zur behandlung endo-ostealer materialien
DE69625690D1 (de) Verfahren zur vorbeugung und behandlung von allergien
EP0835106A4 (de) Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten
DE69807538D1 (de) Vorrichtung und Verfahren zur Behandlung von Gewebe
DE69918306D1 (de) Verfahren und vorrichtung zur behandlung von arrythmien
DE69730097D1 (de) Verfahren und Vorrichtung zur Behandlung von Wafers
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
DE69712504D1 (de) Verfahren zur behandlung eines ammoniak enthaltenden abwasser
DE69632598D1 (de) Vorrichtung und Verfahren zum Bestimmen des Standorts von Objekten
DE69636451D1 (de) Verfahren zur korrosionsinhibierung unter verwendung von n-halo-azolen
DE69512017D1 (de) Verfahren zur behandlung duch hydroisomerizierung von einsätze aus fisher-tropshverfahren
DE69628073D1 (de) Vorrichtung und Verfahren zur Verwaltung von Objektsammlungen
DE69617310D1 (de) Vorrichtung und Verfahren zur Reinigung von Abwasser
ATE204120T1 (de) Verfahren zur vermehrung von pflanzenmaterial
DE60023623D1 (de) Vorrichtung und Verfahren zur Behandlung leicht polymerisierbarer Komponenten
ATE297124T1 (de) Verfahren und vorrichtung zur behandlung von frischfleisch
DE60020050D1 (de) Verfahren und Vorrichtung zur Ortung der Quelle von Teilentladungen
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
DE69534533D1 (de) Vorrichtung und verfahren zur verteilung von betriebsmitteln eines physischen netzwerkes
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE371453T1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
EP0909172A4 (de) Verfahren und zusammensetzungen zur behandlung von harninkontinenz unter verwendung von enantiomer-angereichertem (r,s)-glycopyrrolat

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHAHINFAR, SHAHNAZ

Inventor name: OWEN, ROGER, A.

Inventor name: EYDELLOTH, RONALD, S.

Inventor name: REMUZZI, GIUSEPPE

A4 Supplementary search report drawn up and despatched

Effective date: 19980814

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010103